In the Matter of the Suspension or Revocation of the License of Kieran Slevin, M.D., Etc.

CourtNew Jersey Superior Court Appellate Division
DecidedApril 2, 2026
DocketA-0168-24
StatusUnpublished

This text of In the Matter of the Suspension or Revocation of the License of Kieran Slevin, M.D., Etc. (In the Matter of the Suspension or Revocation of the License of Kieran Slevin, M.D., Etc.) is published on Counsel Stack Legal Research, covering New Jersey Superior Court Appellate Division primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In the Matter of the Suspension or Revocation of the License of Kieran Slevin, M.D., Etc., (N.J. Ct. App. 2026).

Opinion

NOT FOR PUBLICATION WITHOUT THE APPROVAL OF THE APPELLATE DIVISION This opinion shall not "constitute precedent or be binding upon any court ." Although it is posted on the internet, this opinion is binding only on the parties in the case and its use in other cases is limited . R. 1:36-3.

SUPERIOR COURT OF NEW JERSEY APPELLATE DIVISION DOCKET NO. A-0168-24

IN THE MATTER OF THE SUSPENSION OR REVOCATION OF THE LICENSE OF

KIERAN SLEVIN, M.D. LICENSE NO. 25MA8620600

TO PRACTICE MEDICINE AND SURGERY IN THE STATE OF NEW JERSEY. ____________________________

Argued March 3, 2026 – Decided April 2, 2026

Before Judges Gilson, Perez Friscia, and Vinci.

On appeal from the New Jersey State Board of Medical Examiners, Division of Consumer Affairs, Department of Law and Public Safety.

Andrew Gimigliano argued the cause for appellant Kieran Slevin, M.D. (Mandelbaum Barrett PC, attorneys; Andrew Gimigliano, Mohamed H. Nabulsi, Michael S. Kivowitz and Marlene M. Arabia, on the briefs).

David M. Puteska, Deputy Attorney General, argued the cause for respondent New Jersey State Board of Medical Examiners (Jennifer Davenport, Attorney General, attorney; Donna Arons, Assistant Attorney General, of counsel; David M. Puteska, on the brief).

PER CURIAM

Kieran Slevin, a medical doctor, appeals from a final administrative

decision and order of the State Board of Medical Examiners (the Board). In its

decision, the Board found that Slevin had failed to comply with medical

recordkeeping obligations and had intentionally and materially altered medical

records in violation of N.J.S.A. 45:1-21(e) and (h). As penalties, the Board

suspended Slevin's license to practice medicine for six months, imposed a

$150,000 fine, and directed Slevin to pay $98,835 in fees and costs.

Slevin contends the Board's findings are not supported by substantial

credible evidence and are arbitrary, capricious, and unreasonable. He also

asserts that the penalties imposed were disproportionate to the violations found.

Having reviewed the record and law, including the evidence developed at a

hearing before an administrative law judge (ALJ), we affirm the Board's

decisions and the penalties imposed because they are supported by substantial

credible evidence, are consistent with the law, and are not arbitrary, capricious,

or unreasonable.

A-0168-24 2 I.

Slevin is licensed to practice medicine in New Jersey, New York,

Pennsylvania, and Delaware. His medical specialties are anesthesiology and

interventional pain management. As part of his experience, Slevin worked at

the University of Pennsylvania as an assistant professor and conducted research

on the safety and efficacy of fentanyl products.

In 2011, Slevin began working for the Virtua Health System (Virtua), as

chief of pain medicine for Virtua's southern New Jersey campuses. Thereafter,

Slevin left Virtua and opened his own practice under the name North American

Spine & Pain Consultants (NA Pain Consultants).

Beginning at Virtua and continuing at NA Pain Consultants, Slevin treated

several patients with Subsys, which is a Transmucosal Immediate Release

Fentanyl (TIRF) medication. In 2012, Subsys was approved by the federal Food

and Drug Administration (FDA) as a treatment for pain in adult cancer patients.

Subsys is a potent pain medication, which has possible side effects, including

overdose and death.

Outpatient prescription of Subsys was limited to patients enrolled in the

TIRF Risk Evaluation and Mitigation Strategy (REMS) access program

administered by the FDA. The TIRF REMS program required physicians

A-0168-24 3 prescribing Subsys on an outpatient basis to execute TIRF REMS agreements

and keep detailed records of prescription information.

In 2016, the New Jersey Attorney General (AG) investigated Slevin

concerning his prescriptions of Subsys. In October 2016, the AG issued a

document subpoena for Slevin's medical records related to his treatment of five

patients. Slevin responded to the subpoena by producing records and certifying

that the records were accurate and complete (the First Set of records).

Following a subsequent request for records in 2018, Slevin produced a

Second Set of records (the Second Set of records). Slevin certified the Second

Set of records were accurate and complete.

In November 2020, the AG filed a five-count administrative complaint

against Slevin with the Board. In the first four counts, the AG alleged that

Slevin's practice of medicine violated the standard of care because he had

recklessly prescribed Subsys to four patients.

The AG also alleged Slevin engaged in professional misconduct in his

recordkeeping, and he failed to comply with the Board's administrative

regulations concerning recordkeeping. In that regard, the AG alleged that Slevin

had violated N.J.S.A. 45:1-21(e) and (h). Concerning the violation of N.J.S.A.

45:1-21(h), the AG asserted that the two sets of medical records Slevin produced

A-0168-24 4 for four patients "differ[ed] in their completeness and in internal editing," and

did "not meet the 'contemporaneous permanent professional treatment records'

standards set forth in the Board['s] regulation[,] N.J.A.C. 13:35-6.5."

Slevin filed an answer, denying the allegations. The parties then engaged

in discovery and the matter proceeded to a contested hearing before an ALJ in

the Office of Administrative Law. The hearing was conducted over seven days

between May and August 2023. At the hearing, the AG submitted numerous

documents into evidence, including the First and Second Sets of records. The

AG also called a medical expert, Christopher Gharibo, M.D. Slevin testified

and called a medical expert, Jeffrey Gudin, M.D. Three of Slevin's patients also

testified on his behalf.

In his testimony, Slevin explained his treatment and prescription of

Subsys to the four patients. He also described his medical recordkeeping related

to those four patients. Slevin acknowledged that there were differences between

the First Set of records and the Second Set of records. He also admitted that he

had edited the medical records before producing the Second Set of records.

The two medical experts, both of whom were experts in pain management,

offered differing opinions concerning whether Slevin's treatment of the four

patients was within the standard of care, including the prescription of Subsys.

A-0168-24 5 In terms of the medical records, Dr. Gharibo opined that Slevin's

recordkeeping was inadequate. He testified that Slevin's documentation was not

specific and largely consisted of copying and pasting information from prior

examinations. He also opined that the records did "not account for the extent

and complexity of the controlled substance dosing" and did "not justify the

opioid-heavy plan of care." Slevin's expert, Dr. Gudin, acknowledged some

deficiencies in Slevin's recordkeeping and that Slevin had undated edits to the

records, which did not comply with regulations on medical recordkeeping.

On March 5, 2024, the ALJ issued his initial decision, finding that Slevin

had met the standard of care when treating the four patients and that he had not

exhibited gross negligence when prescribing Subsys. So, the ALJ found the AG

failed to prove that Slevin had violated professional medical standards in

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re Herrmann
926 A.2d 350 (Supreme Court of New Jersey, 2007)
In Re the Suspension or Revocation of the License Issued Zahl
895 A.2d 437 (Supreme Court of New Jersey, 2006)
In Re the Revocation of the License of Polk
449 A.2d 7 (Supreme Court of New Jersey, 1982)
Rosenblit v. Zimmerman
766 A.2d 749 (Supreme Court of New Jersey, 2001)
In Re Taylor
731 A.2d 35 (Supreme Court of New Jersey, 1999)
In Re Kim
958 A.2d 485 (New Jersey Superior Court App Division, 2008)
Public Advocate Dep't v. Public Utilities Bd.
460 A.2d 1057 (New Jersey Superior Court App Division, 1983)
Shortino v. Buna
48 A.3d 401 (New Jersey Superior Court App Division, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
In the Matter of the Suspension or Revocation of the License of Kieran Slevin, M.D., Etc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-the-matter-of-the-suspension-or-revocation-of-the-license-of-kieran-njsuperctappdiv-2026.